PURPOSE: To quantify costs of eye care providers' Medicare Part D prescribing patterns for ophthalmic medications and to estimate the potential savings of generic or therapeutic dr
PURPOSE: To examine demographic and geographic variation in the use of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Med
Cataracts are a leading cause of reversible blindness in India, where millions of people can be effectively treated for this condition with surgery.
IMPORTANCE: Anti-vascular endothelial growth factor (VEGF) medicines have revolutionized diabetic macular edema (DME) treatment.
Aflibercept and ranibizumab were less cost-effective than bevacizumab in the treatment of diabetic macular edema, according to a post hoc analysis of data from the Diabetic Retinopathy Clinical Res
